Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698423 | 0.98 | HRH4 (0.42) | HRH4HRH3PKMHTTATM | |
| SCHEMBL18232436 | 0.98 | HRH4 (0.42) | HRH4HRH3PKMHTTATM | |
| SCHEMBL6692244 | 0.92 | — | — | |
| SCHEMBL9624660 | 0.87 | HRH4 (0.47) | HRH4HRH3PKMEPHX1ANPEP | |
| SCHEMBL24379824 | 0.84 | HRH4 (0.48) | HRH4HRH3PKMEPHX1ANPEP | |
| SCHEMBL5298781 | 0.84 | HRH4 (0.48) | HRH4HRH3PKMEPHX1ANPEP | |
| SCHEMBL2483497 | 0.84 | HRH4 (0.48) | HRH4HRH3PKMEPHX1ANPEP | |
| SCHEMBL20996688 | 0.83 | KMT2A (0.41) | PKMHTTATMNPSR1ANPEP | |
| SCHEMBL605994 | 0.81 | — | — | |
| SCHEMBL9494047 | 0.81 | KMT2A (0.41) | PKMANPEPCA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004533516-A | — | — | 2004-11-04 | — | — | JP | claimed |
| US-20040134838-A1 | Method of refining crude oils having organic acidity | TOTAL FRANCE (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1397468-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | Total France (FR) | 2004-03-17 | — | — | EP | claimed |
| WO-2002097014-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | TOTAL FRANCE (FR) | 2002-12-05 | — | — | WO | claimed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| CN-113423702-A | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| US-20040134838-A1 | Method of refining crude oils having organic acidity | TOTAL FRANCE (FR) | 2004-07-15 | — | — | US | disclosed |
| EP-1397468-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | Total France (FR) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002097014-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | TOTAL FRANCE (FR) | 2002-12-05 | — | — | WO | disclosed |
| US-4452710-A | AMINE SALTS OF CARBOXYLIC ACID TERMINATED AMIDES | CINCINNATI MILACRON INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4383937-A | Aqueous functional fluid compositions | CINCINNATI MILACRON INC. (US) | 1983-05-17 | — | — | US | disclosed |
| US-4379063-A | Novel functional fluid | CINCINNATI MILACRON INC. (US) | 1983-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | HRH4 530/4885HRH3 2237/4885PKM 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.